International Journal of Research Publication and Reviews

Clinical Evidence on Berberine for Weight Loss

Danika Manocha

Department of Nutrition & Dietetics, Desh Bhagat University, Pubjab, India

A B S T R A C T

Berberine, a naturally occurring alkaloid found in several medicinal plants, has long been utilized in traditional medicine for its antimicrobial and gastrointestinal benefits. Recent research has revealed its multifaceted pharmacological properties, including antihyperglycemic, lipid-lowering, anti-inflammatory, antioxidant, hepatoprotective, and cardioprotective effects. This review summarizes clinical evidence on berberine's impact on weight-related outcomes and metabolic health. Multiple randomized controlled trials and meta-analyses indicate that berberine supplementation modestly reduces body weight, body mass index, waist circumference, visceral fat, and hepatic fat accumulation, even when overall weight loss is limited. These effects appear to be mediated through improvements in insulin sensitivity, lipid metabolism, and hepatic fat regulation. Berberine also consistently improves lipid profiles, lowering triglycerides, LDL cholesterol, and total cholesterol, with minimal reported adverse effects. However, the overall strength of evidence is limited by small sample sizes, short intervention durations, and methodological variability. While berberine shows promise as an adjunctive therapy for central obesity and metabolic dysfunction, its efficacy as a primary weight-loss agent remains modest. Further high-quality, long-term clinical trials are warranted to establish its safety, efficacy, and optimal dosing in diverse populations.

Keywords: Berberine, obesity, weight loss, metabolic health, lipid profile, nutrition, supplements

1. Introduction

Berberine is a quaternary benzylisoquinoline alkaloid with a long history of use in traditional Ayurvedic and Chinese medicine. It naturally occurs in several medicinal plants, including Berberis aristata (Daruharidra/Tree Turmeric), Coptis chinensis, and Hydrastis canadensis. Today, most clinical preparations use synthetically produced berberine salts, such as berberine chloride or sulfate. Recognizable by its bright yellow color and characteristic bitter taste, berberine was historically valued for its strong antimicrobial and antidiarrheal properties. (Kumar et al., 2015)

In recent decades, extensive research has demonstrated that berberine possesses a wide range of pharmacological effects. These include antihyperglycemic, lipid-lowering, anti-inflammatory, antioxidant, neuroprotective, hepatoprotective, and cardioprotective actions. Berberine has also shown activity against drug-resistant bacteria and certain viruses, further highlighting its potential as a versatile natural therapeutic agent. (Mushtaq et al., 2023)

Berberine is widely regarded as a potent nutraceutical with multiple health benefits. Although its intestinal absorption is limited, berberine concentrates effectively in tissues, enabling significant physiological activity. Mechanistically, it modulates microRNA activity, gene expression, apoptosis, and various cellular signaling pathways, contributing to its antidiabetic, anti-obesity, anti-inflammatory, antioxidant, neuroprotective, hepatoprotective, cardioprotective, and anti-aging effects. Additionally, berberine may help prevent chronic diseases and certain cancers, emphasizing its broad therapeutic potential. (Mushtaq et al., 2023)

Berberine is commercially available over the counter as a dietary supplement, either alone or in combination with other herbs and nutrients. Typical recommended doses range from 250 mg to 500 mg, taken two to three times daily depending on the formulation and intended use. However, berberine has not been FDA-approved to treat any medical condition, and its long-term safety and efficacy in humans remain under investigation. (Key, 2020)

2. Review of Literature

Asbaghi et al. (2020) did a systematic review and meta-analysis of 12 randomized controlled trials which evaluated the effects of berberine on obesity-related outcomes. Berberine supplementation led to a significant reduction in body weight (–2.07 kg), BMI (–0.47 kg/m²), and waist circumference (–1.08 cm) compared with control groups (all p < 0.05). It also decreased systemic inflammation, shown by a drop in CRP levels (–0.42 mg/L). No significant changes were found in liver enzyme markers (ALT, AST), indicating metabolic benefits without evidence of liver toxicity. Overall, the findings suggest that berberine produces modest but meaningful improvements in weight and adiposity parameters, supporting its role in metabolic and obesity management.

Yan et al. (2015) conducted a study that evaluated berberine (0.5 g, three times daily) in Non-Alcoholic Fatty Liver Disease (NAFLD) patients alongside lifestyle intervention for 16 weeks. The berberine group showed a 52.7% reduction in hepatic fat content, significantly greater than the 36.4% reduction seen with lifestyle changes alone. Berberine also produced significant improvements in body weight, insulin resistance (HOMA-IR), and serum lipid profile (all p < 0.05), outperforming the standard drug pioglitazone. These improvements occurred even when weight loss was similar, suggesting a direct metabolic effect on liver fat regulation. Overall, the findings support berberine's efficacy in reducing fat accumulation, improving lipids, and enhancing metabolic health in NAFLD patients.

Kong et al. (2025) studied various non-randomized and randomized trials: one small trial with 10 people on Berberine (500 mg thrice daily) for 12 weeks showed ~ 2.3 kg average weight loss plus ~ 12.2% drop in total cholesterol (TC) and ~ 23% drop in triglycerides (TG). Other trials with ~ 1.5 g/day Berberine for 3 months documented reductions in waist circumference, body-mass index (BMI), visceral fat proportion, trunk fat, and improved liver fat (less steatosis) in obese or pre-diabetic subjects.

Liu et al. (2025) did a systematic review and meta-analysis of 12 randomized placebo-controlled trials (~889 participants) that evaluated berberine's impact on metabolic syndrome. Berberine produced significant metabolic improvements, including a reduction in triglycerides (–0.367 mmol/L), fasting plasma glucose (–0.515 mmol/L), and waist circumference (–3.27 cm). It also lowered LDL-C (–0.495 mmol/L), total cholesterol (–0.451 mmol/L), and BMI (–0.435 kg/m²). These findings indicate that berberine meaningfully improves glucose and lipid parameters while reducing central adiposity. Overall, the study supports berberine as a safe and effective supplement for improving metabolic dysfunction and features related to obesity.

Xiong et al. (2020) carried out a meta-analysis to pool data from 10 clinical trials and found that Berberine supplementation significantly reduced body-mass index (BMI) by −0.29 kg/m² (95% CI: −0.51 to −0.08, p = 0.006) and waist circumference (WC) by −2.75 cm (95% CI: −4.88 to −0.62, p = 0.01). However, the reduction in actual body weight was small and not statistically significant (weighted mean difference: −0.11 kg; 95% CI: −0.99 to 0.76, p = 0.79). On dose-response analysis, longer duration of berberine use was associated with greater reductions in BMI and waist circumference.

Shi et al. (2025) summarized 54 systematic reviews covering many health outcomes linked to berberine. The authors found that across these reviews, berberine was associated with improvements in metabolic syndrome, dyslipidemia, type 2 diabetes, and other chronic conditions. Specifically for obesity-related outcomes, about 57% (4 of 7) of the obesity-focused reviews reported beneficial effects. However, the methodological quality was often poor — 45 of the 54 reviews were rated "critically low," 8 as "low," and only 1 as "high quality." Thus, while there is some supportive evidence for berberine's role in improving weight-related parameters and lipid/metabolic health, the strength of evidence remains limited and should be interpreted with caution.

Derosa et al. (2013) performed a randomized, placebo-controlled trial in 144 adults with low cardiovascular risk to evaluate berberine 500 mg twice daily for 3 months. Berberine supplementation significantly improved the lipid profile, producing reductions in total cholesterol (TC), triglycerides (TG), and LDL-C, while increasing HDL-C compared with placebo. During a washout period, lipid levels worsened, but reintroduction of berberine restored the improvements, confirming the effect. The study demonstrates that berberine can modestly but meaningfully improve lipid metabolism, supporting its potential role in managing dyslipidemia and cardiovascular risk.

Dong et al. (2013) analyzed 11 randomized controlled trials (total 874 participants) to assess how Berberine affects blood lipid levels. Compared with control, berberine produced significant reductions in total cholesterol (TC, –0.61 mmol/L), triglycerides (TG, –0.50 mmol/L), and LDL-cholesterol (LDL-C, –0.65 mmol/L). It also caused a modest but significant increase in HDL-cholesterol (HDL-C, +0.05 mmol/L). No serious adverse effects were reported. The authors concluded that berberine appears effective at improving lipid profiles, though they noted that the methodological quality of the included trials was generally low and advocated for larger, higher-quality studies to confirm its value.

Table 1 - Berberine's effects on weight loss, BMI, waist circumference, fat, and lipid parameters

Study	Population & Sample Size	Berberine Dose & Duration	Key Findings (Weight / Obesity-related outcomes)	Lipid / Metabolic Effects
NAFLD Study (PLOS One)	NAFLD patients	0.5 g, 3x/day, 16 weeks	52.7% reduction in hepatic fat; improved body weight	Improved HOMA-IR and serum lipids; outperformed pioglitazone
Systematic Review & Meta-analysis (PubMed)	12 RCTs	-	Body weight –2.07 kg; BMI –0.47 kg/m²; WC –1.08 cm	CRP –0.42 mg/L; no significant change in ALT/AST
Small Trial (PMC)	10 obese/pre-diabetic	500 mg, 3x/day, 12 weeks	Avg weight loss ~2.3 kg	TC ↓12.2%, TG ↓23%
Systematic Review & Meta-analysis (PMC, 2025)	12 RCTs (~889 participants)	~1.5 g/day, 3 months	BMI –0.435 kg/m²; WC –3.27 cm	TG –0.367 mmol/L; FPG –0.515 mmol/L; LDL-C –0.495 mmol/L; TC –0.451 mmol/L

Study	Population & Sample Size	Berberine Dose & Duration	Key Findings (Weight / Obesity-related outcomes)	Lipid / Metabolic Effects
Dose-response Meta-analysis (ScienceDirect, 2025)	10 clinical trials	-	BMI –0.29 kg/m²; WC –2.75 cm; weight change not significant	–
Umbrella Review (BMC, 2025)	54 systematic reviews	-	57% of obesity-focused reviews reported weight-related benefits	–
RCT, Low CV Risk (Expert Opinion, 2013)	144 adults	500 mg, 2x/day, 3 months	Modest body weight reduction	TC, TG, LDL-C ↓; HDL-C ↑
Meta-analysis (Thieme E-Journals, 2013)	11 RCTs (874 participants)	-	–	TC –0.61 mmol/L; TG –0.50 mmol/L; LDL-C –0.65 mmol/L; HDL-C +0.05 mmol/L

4. Conclusion

The current body of evidence suggests that berberine exerts modest but meaningful benefits on weight-related outcomes, particularly in reducing body mass index, waist circumference, visceral fat, and hepatic fat accumulation. Across multiple randomized controlled trials and meta-analyses, berberine consistently demonstrates improvements in central adiposity, even when overall weight loss is limited. Studies in patients with metabolic dysfunction and NAFLD indicate that berberine's metabolic benefits may occur independent of major changes in body weight, suggesting a direct effect on lipid metabolism, insulin sensitivity, and hepatic fat regulation. Furthermore, its lipid-lowering and glucose-modulating properties appear robust, with most reviews reporting reductions in triglycerides, LDL cholesterol, total cholesterol, and fasting glucose. However, evidence quality remains variable; several systematic reviews highlight methodological limitations, small sample sizes, and short intervention durations that restrict the strength of conclusions. Overall, available literature supports berberine as a potentially effective adjunctive therapy for improving metabolic health and central obesity, though its role as a primary weight-loss agent remains limited. More high-quality, long-term clinical trials are needed to confirm its efficacy and safety in broader populations.

References

Asbaghi, O., Ghanbari, N., shekari, M., Reiner, Ž., Amirani, E., Hallajzadeh, J., Mirsafaei, L., & Asemi, Z. (2020). *The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials*. Clinical Nutrition ESPEN, 38, 43–49. https://doi.org/10.1016/j.clnesp.2020.04.010

Derosa, G., D'Angelo, A., Bonaventura, A., Bianchi, L., Romano, D., & Maffioli, P. (2013). *Effects of berberine on lipid profile in subjects with low cardiovascular risk*. Expert Opinion on Biological Therapy, 13(4), 475–482. https://doi.org/10.1517/14712598.2013.776037

Dong, H., Zhao, Y., Zhao, L., & Lu, F. (2013). *The Effects of Berberine on Blood Lipids: A Systemic Review and Meta-Analysis of Randomized Controlled Trials*. Planta Medica, 79(06), 437–446. https://doi.org/10.1055/s-0032-1328321

Key, A. P. (2020, November 13). *Berberine: Benefits and Side Effects*. WebMD. https://www.webmd.com/obesity/berberine-health-benefits

Kong, Y., Yang, H., Nie, R., Zhang, X., Zhang, H., & Xin Nian. (2025). *Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence*. European Journal of Medical Research, 30(1). https://doi.org/10.1186/s40001-025-02738-6

Kumar, A., Ekavali, Chopra, K., Mukherjee, M., Pottabathini, R., & Dhull, D. K. (2015). *Current knowledge and pharmacological profile of berberine: An update*. European Journal of Pharmacology, 761, 288–297. https://doi.org/10.1016/j.ejphar.2015.05.068

Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H. (2025). *Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials*. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1572197

Mushtaq, Z., Imran, M., Saeed, F., Imran, A., Ali, S. W., Shahbaz, M., Alsagaby, S. A., Guerrero Sánchez, Y., Umar, M., Hussain, M., Al Abdimonem, W., Al Jbawi, E., Mahwish, El-Ghorab, A. H., & Abdelgawad, M. A. (2023). *Berberine: a comprehensive approach to combat human maladies*. International Journal of Food Properties, 26(1), 787–807. https://doi.org/10.1080/10942912.2023.2184300

Shi, L., Wang, W., Jing, C., Hu, J., & Liao, X. (2025). *Berberine and health outcomes: an overview of systematic reviews*. BMC Complementary Medicine and Therapies, 25(1). https://doi.org/10.1186/s12906-025-04872-4

Xiong, P., Niu, L., Talaei, S., Kord-Varkaneh, H., Clark, C. C. T., Găman, M.-A., Rahmani, J., Dorosti, M., Mousavi, S. M., Zarezadeh, M., Taghizade-Bilondi, H., & Zhang, J. (2020). *The effect of berberine supplementation on obesity indices: A dose–response meta-analysis and systematic review of randomized controlled trials*. Complementary Therapies in Clinical Practice, 39, 101113. https://doi.org/10.1016/j.ctcp.2020.101113

Yan, H.-M., Xia, M.-F., Wang, Y., Chang, X.-X., Yao, X.-Z., Rao, S.-X., Zeng, M.-S., Tu, Y.-F., Feng, R., Jia, W.-P., Liu, J., Deng, W., Jiang, J.-D., & Gao, X. (2015). *Efficacy of berberine in patients with Non-Alcoholic Fatty Liver Disease*. PLOS ONE, 10(8), e0134172. https://doi.org/10.1371/journal.pone.0134172